Indicator of whether hemodynamic augmentation is being given to the subject/participant
Registration Status:
Qualified
Permissible Values:
Data Type:
Value List
Unit of Measure:
Ids:
Value
Code Name
Code
Code System
Code Description
Yes, specify
Yes, specify
Yes, specify
No
No
No
Designations:
Designation:
Hemodynamic augmentation indicator
Tags:
Designations:
Definition:
Indicator of whether hemodynamic augmentation is being given to the subject/participant
Tags:
Reference Documents:
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES Jr, Citerio G, Gress D, H?nggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zipfel G; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211–240. • Suarez JI, Martin RH. Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design. Neurocrit Care. 2010;13(2):263–277. • Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL, Wong J, Harbaugh R; ALISAH Investigators. The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke. 2012;43(3):683–690. • van der Jagt M. Fluid management of the neurological patient: a concise review. Crit Care. 2016;20(1):126. • van der Jagt M, Haitsma I. An injured brain needs cooling down: no. Intensive Care Med. 2015;41(6):1129–1131